5-(4-Propan-2-ylphenyl)pentan-1-ol | 1216244-91-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 5-(4-Propan-2-ylphenyl)pentan-1-ol
• CAS: 1216244-91-5
• 化学式: C₁₄H₂₂O
• 分子量: 206.328
• InChiKey: DUDHXVVPVCDCFJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  5-(4-Propan-2-ylphenyl)pentan-1-ol 在 2-碘酰基苯甲酸 作用下， 以 二甲基亚砜 为溶剂， 以530 mg的产率得到5-(4-isopropylphenyl)pentanal
  参考文献：
  名称：

  Iron-Catalyzed Arene Alkylation Reactions with Unactivated Secondary Alcohols

  摘要：

  A simple, iron-based catalytic system allows for the inter- and intramolecular arylation of unactivated secondary alcohols. This transformation expands the substrate scope beyond the previously required activated alcohols and proceeds under mild reaction conditions, tolerating air and moisture. Furthermore, the use of an enantioenriched secondary alcohol provides an enantioenriched product for the intramolecular reaction, thereby offering a convenient approach to nonracemic products.

  DOI：

  10.1021/ol500606d
• 作为产物：
  描述：

  戊二酸酐 在 盐酸 、 aluminum (III) chloride 、 锌 作用下， 以 二氯甲烷 、 水 为溶剂， 生成 5-(4-Propan-2-ylphenyl)pentan-1-ol
  参考文献：
  名称：

  Iron-Catalyzed Arene Alkylation Reactions with Unactivated Secondary Alcohols

  摘要：

  A simple, iron-based catalytic system allows for the inter- and intramolecular arylation of unactivated secondary alcohols. This transformation expands the substrate scope beyond the previously required activated alcohols and proceeds under mild reaction conditions, tolerating air and moisture. Furthermore, the use of an enantioenriched secondary alcohol provides an enantioenriched product for the intramolecular reaction, thereby offering a convenient approach to nonracemic products.

  DOI：

  10.1021/ol500606d

文献信息

• QUINOXALINE DERIVATIVE AS ANTIDIABETIC AGENT
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP0670831A1

  公开（公告）日：1995-09-13
• SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20220213026A1

  公开（公告）日：2022-07-07

  Disclosed are compounds of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein Q is a 5-membered heterocyclyl or 5-membered heteroaryl having 1 to 4 heteroatoms independently selected from N, O, and S, substituted with zero to 4 R 1 ; and A, X 1 , X 2 , X 3 , X 4 , Z 1 , Z 2 , R 1 , R 2 , R 3a , R 3b , a, b, and d are defined herein. Also disclosed are methods of using these compounds to modulate the activity of farnesoid X receptor (FXR); pharmaceutical compositions comprising these compounds; and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
• [EN] QUINOXALINE DERIVATIVE AS ANTIDIABETIC AGENT<br/>[FR] DERIVES DE QUINOXALINE UTILISES COMME AGENTS ANTIDIABETIQUES
  申请人：OTSUKA PHARMACEUTICAL COMPANY, LIMITED

  公开号：WO1995009159A1

  公开（公告）日：1995-04-06

  (EN) Quinoxaline derivatives of formula (1), and salts thereof, which have excellent antidiabetic activity, and an antidiabetic agent comprising as an active ingredient the quinoxaline derivative or a pharmaceutically acceptable salt thereof.(FR) Sont décrits des dérivés de quinoxaline de formule (1) et leurs sels qui possèdent une excellente activité antidiabétique, ainsi qu'un agent antidiabétique renfermant comme principe actif ce dérivé de quinoxaline ou bien un sel pharmaceutiquement acceptable de celui-ci.